A Phase 2 interventional study of Droxidopa and Pyridostigmine in Orthostatic Hypotension, sponsored by Mayo Clinic. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Mayo Clinic · Phase 2, Interventional, and Treatment
Among 15 studies testing droxidopa in Hypotension, Orthostatic — 2 open to participants now, 2 under way, none of them phase 3. Droxidopa · Hypotension, Orthostatic.
Among the 15 studies testing droxidopa in Hypotension, Orthostatic, this one is the 7th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2011, is one of 2 in phase 2, and was the 9th registered.
159 studies on the registry are indexed under Hypotension, Orthostatic; 35 are open to participants now.
Browse Hypotension, Orthostatic studies →2 of the 15 studies testing droxidopa in Hypotension, Orthostatic are open now, in 1 country. Recruiting first, the newest first:
Stephen G. Kaler · Sites in United States
Ages 7–17
By country, each count listing its studies:
Droxidopa: first FDA approval 2014 (NORTHERA). What it is approved for, and how studies give it, is on its page →
Of the 23 Hypotension, Orthostatic studies recruiting now, 8 (35%) set no upper age limit and 8 (35%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 7 · Phase 4 2
First in 1999; this study’s year is marked. 1 started in 2011.
This study's planned enrollment of 30 is close to the median of 28 across 113 interventional studies indexed under Hypotension, Orthostatic.
Median enrollment 28 across the 14 interventional studies. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 15 have an industry lead sponsor. The 10 most frequent:
Mayo Clinic is the lead sponsor of 3,270 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 321 (71%) have results posted.
Mayo Clinic has 3 studies filed under Hypotension, Orthostatic — fewer than ten, so there is no comparison to draw.
1 of the studies testing droxidopa in Hypotension, Orthostatic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01370512Mayo ClinicDroxidopa / Pyridostigmine in Orthostatic Hypotension | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing droxidopa in Hypotension, Orthostatic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being done to study the combination of pyridostigmine and low-dose Droxidopa for the treatment of orthostatic hypotension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
participants first receive placebo by mouth 3 times a day, for treatment day 1. Then participants receive pyridostigmine by mouth 3 times a day for treatment day 2.
Drug: Pyridostigmine · Other: Placebo
participants first receive pyridostigmine by mouth 3 times a day, for treatment day 1. Then participants receive placebo by mouth 3 times a day for treatment day 2.
Drug: Pyridostigmine · Other: Placebo
participants first receive placebo by mouth 3 times a day, for treatment day 3. Then participants receive Droxidopa by mouth 3 times a day for treatment day 4.
Drug: Droxidopa · Drug: Pyridostigmine · Other: Placebo
participants first receive Droxidopa by mouth 3 times a day, for treatment day 3. Then participants receive Placebo by mouth 3 times a day for treatment day 4.
Drug: Droxidopa · Drug: Pyridostigmine · Other: Placebo
100 mg tablets by mouth three times a day
60 mg tablets by mouth three times a day
Looks exactly like the study drug but contains no active ingredients
Change in orthostatic diastolic blood pressure
diastolic blood pressure measured upon standing reported in mm/Hg
Time frame: 1 hour after medication administration, 2 hours after medication administration
Change in orthostatic systolic blood pressure
systolic blood pressure measured upon standing reported in mm/Hg
Time frame: 1 hour after medication administration, 2 hours after medication administration
Change in absolute supine diastolic blood pressure
diastolic blood pressure measured while lying flat reported in mm/Hg
Time frame: 1 hour after medication administration, 2 hours after medication administration
Change in absolute supine systolic blood pressure
systolic blood pressure measured while lying flat reported in mm/Hg
Time frame: 1 hour after medication administration, 2 hours after medication administration
Change in supine norepinephrine levels
measure of serum norepinephrine levels while lying flat reported in pg/mL
Time frame: 1 hour after medication administration, 2 hours after medication administration
Change in orthostatic symptoms
measured during tilt study, the patient will be asked to score orthostatic symptoms on a symptom scale ranging from "0" = no symptoms to "10" = near syncope
Time frame: 1 hour after medication administration, 2 hours after medication administration
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Nov 2011, a primary completion of May 2027 and a completion of May 2027. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Droxidopa